Comparative tuberculosis (TB) prevention effectiveness in children of Bacillus Calmette-Guérin (BCG) vaccines from different sources, Kazakhstan

Michael Favorov, Mohammad Ali, Aigul Tursunbayeva, Indira Aitmagambetova, Paul Kilgore, Shakhimurat Ismailov, Terence Chorba, Michael Favorov, Mohammad Ali, Aigul Tursunbayeva, Indira Aitmagambetova, Paul Kilgore, Shakhimurat Ismailov, Terence Chorba

Abstract

Background: Except during a 1-year period when BCG vaccine was not routinely administered, annual coverage of infants with Bacillus Calmette-Guérin (BCG) in Kazakhstan since 2002 has exceeded 95%. BCG preparations from different sources (Japan, Serbia, and Russia) or none were used exclusively in comparable 7-month time-frames, September through March, in 4 successive years beginning in 2002. Our objective was to assess relative effectiveness of BCG immunization.

Methods/findings: We compared outcomes of birth cohorts from the 4 time-frames retrospectively. Three cohorts received vaccine from one of three manufacturers exclusively, and one cohort was not vaccinated. Cohorts were followed for 3 years for notifications of clinical TB and of culture-confirmed TB, and for 21 months for TB meningitis notifications. Prevention effectiveness based on relative risk of TB incidence was calculated for each vaccinated cohort compared to the non-vaccinated cohort. Although there were differences in prevention effectiveness observed among the three BCG vaccines, all were protective. The Japanese vaccine (currently used in Kazakhstan), the Serbian vaccine, and the Russian vaccine respectively were 69%, 43%, and 22% effective with respect to clinical TB notifications, and 92%, 82%, and 51% effective with respect to culture confirmed TB. All three vaccines were >70% effective with respect to TB meningitis.

Limitations: Potential limitations included considerations that 1) the methodology used was retrospective, 2) multiple risk factors could have varied between cohorts and affected prevention effectiveness measures, 3) most cases were clinically diagnosed, and TB culture-positive case numbers and TB meningitis case numbers were sparse, and 4) small variations in reported population TB burden could have affected relative risk of exposure for cohorts.

Conclusions/significance: All three BCG vaccines evaluated were protective against TB, and prevention effectiveness varied by manufacturer. When setting national immunization policy, consideration should be given to prevention effectiveness of BCG preparations.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1. Cohorts of vaccinated and non-vaccinated…
Figure 1. Cohorts of vaccinated and non-vaccinated children in Kazakhstan, 2002–2006.
Figure 2. Moving average (2-month) TB notification…
Figure 2. Moving average (2-month) TB notification rate of different birth cohorts born in September–March, by type of BCG administered, Kazakhstan, 2002–2008.
Figure 3. Survivor curve person-year analyses for…
Figure 3. Survivor curve person-year analyses for reported incidence of active TB among different BCG vaccinated and non-vaccinated birth cohorts, Kazakhstan, 2002–2008.

References

    1. Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of published literature. JAMA. 1994;271:698–702.
    1. Comstock GW. Simple, practical ways to assess the protective efficacy of a new tuberculosis vaccine. Clin Infect Dis. 2000;30(Suppl 3):S250–253.
    1. Romanus V. Tuberculosis in bacillus Calmette-Guérin immunized and non-immunized children in Sweden: a ten years evaluation following cessation of general bacillus Calmette-Guérin immunization of the newborn in 1975. Pediatr Infect Dis J. 1987;6:272–280.
    1. Hart PD, Sutherland I. BCG and vole bacillus vaccine in the prevention of tuberculosis in adolescence and early adult life. Br Med J. 1977;2(6082):293–5.
    1. Tuberculosis Research Centre (ICMR), Chennai. Fifteen year follow up of trial of BCG vaccines in south India for tuberculosis prevention. Indian J Med Res. 1999;110:56–69.
    1. Clemens JD, Chuong JJ, Feinstein AR. The BCG controversy. A methodological and statistical reappraisal. JAMA. 1983;249:2362–2369.
    1. Padungchan S, Konjanart S, Kasiratta S, Daramas S, ten Dam HG. The effectiveness of BCG vaccination of the newborn against childhood tuberculosis in Bangkok. Bull World Health Organ. 1986;64:247–258.
    1. Tidjani O, Amedome A, ten Dam HG. The protective effect of BCG vaccination of the newborn against childhood tuberculosis in an African community. Tubercle. 1986;67:269–281.
    1. World Health Organization. WHO-UNICEF Estimates of Immunization Coverage: the Republic of Kazakhstan, 2011. 2011. Available: .
    1. National Center for Tuberculosis. [Ismailov SS, Baimukhanova KX, Belinskaya GD, Tursynbaeva GS, eds.] Annual tuberculosis statistical review, Republic of Kazakhstan [in Russian] Almaty, Kazakhstan: Etamp Asia Publishers, 2007; 2007. [and annual editions of this report from 2002–2006]
    1. Agency of Statistics of the Republic of Kazakhstan. 2011. Multiple websites; Available: .
    1. Smith PG, Morrow RH, editors. Field Trials of Health Interventions in Developing Countries. A Toolbox. 2nd edition. London: Macmillan Education Limited; 1996.
    1. Shapiro C, Cook N, Evans D, Willett W, Fajardo I, et al. A case-control study of BCG and childhood tuberculosis in Cali, Colombia. Int J Epidemiol. 1985;14:441–446.
    1. Sirinavin S, Chotpitayasunondh T, Suwanjutha S, Sunakorn P, Chantarojanasiri T. Protective efficacy of neonatal Bacillus Calmette-Guérin vaccination against tuberculosis. Pediatr Infect Dis J. 1991;10:359–365.
    1. Comstock GW. Field trials of tuberculosis vaccines: how could we have done them better? Control Clin Trials. 1994;15:247–276.
    1. von Reyn CF. Routine childhood Bacillus Calmette-Guérin immunization and HIV infection. Clin Infect Dis. 2006;42:559–561.
    1. Fine PE. BCG vaccination against tuberculosis and leprosy. Br Med Bull. 1988;44:691–703.
    1. Rodrigues LC, Diwan VK, Wheeler JG. Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis. Int J Epidemiol. 1993;22:1154–1158.
    1. Fine PE. BCG: the challenge continues. Scand J Infect Dis. 2001;33:243–245.
    1. Delogu G, Fadda G. The quest for a new vaccine against tuberculosis. J Infect Dev Ctries. 2009;3:5–15.
    1. Behr MA, Wilson MA, Gill WP, Salamon H, Schoolnik GK, et al. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science. 1999;284:1520–1523.
    1. Brosch R, Gordon SV, Garnier T, Eiglmeier K, Frigui W, et al. Genome plasticity of BCG and impact on vaccine efficacy. Proc Natl Acad Sci USA. 2007;104:5596–5601.
    1. Ritz N, Dutta B, Donath S, Casalaz D, Connell TG, et al. The influence of Bacille Calmette-Guérin vaccine strain on the immune response against tuberculosis. Am J Respir Crit Care Med. 2012;185:213–222.
    1. Svenson S, Källenius G, Pawlowski A, Hamasur B. Towards new tuberculosis vaccines. Hum Vaccin. 2010;6:309–317.
    1. Russell DG, Barry CE, 3rd, Flynn JL. Tuberculosis: What we don't know can, and does, hurt us. Science. 2010;328:852–856.

Source: PubMed

3
Suscribir